Statistical challenges in the evaluation of surrogate endpoints in randomized trials.
about
A perfect correlate does not a surrogate makeThe perils of surrogate endpointsComparing biomarkers as principal surrogate endpointsCenter-Within-Trial Versus Trial-Level Evaluation of Surrogate EndpointsSemiparametric inference for surrogate endpoints with bivariate censored data.Exploring the relationship between surrogates and clinical outcomes: analysis of individual patient data vs. meta-regression on group-level summary statistics.Accommodating missingness when assessing surrogacy via principal stratification.Time and PSA threshold model prognosticates long-term overall and disease-specific survival in prostate cancer patients as early as 3 months after external beam radiation therapy.Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology.Robust estimation of the proportion of treatment effect explained by surrogate marker informationThe Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogatASSESSING SURROGATE ENDPOINTS IN VACCINE TRIALS WITH CASE-COHORT SAMPLING AND THE COX MODEL.Evaluating a surrogate endpoint at three levels, with application to vaccine development.On assessing surrogacy in a single trial setting using a semicompeting risks paradigm.Bioinformatics advances for clinical biomarker development.Statistical evaluation of surrogate endpoints with examples from cancer clinical trials.A Bayesian hierarchical surrogate outcome model for multiple sclerosis.Multiparameter evidence synthesis in epidemiology and medical decision-making.The intermediate endpoint effect in logistic and probit regression.Variation over time and interdependence between disease progression and death among patients with glioblastoma on RTOG 0525.Surrogate measures and consistent surrogatesMagnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis.An entropy-based nonparametric test for the validation of surrogate endpoints.Validation of surrogate markers in multiple randomized clinical trials with repeated measurements: canonical correlation approach.Five criteria for using a surrogate endpoint to predict treatment effect based on data from multiple previous trials.Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy.Evaluation of early efficacy endpoints for proof-of-concept trials.Learning from clinical medicine to improve the use of surrogates in ecology
P2860
Q24803339-333A432A-6337-4F3C-B5F4-69F840CE46FEQ27025740-C3449D99-2E31-4A0C-A687-3AB2E527929BQ28740935-59B9D1D9-D5BE-47A0-853C-358F029EF186Q30370596-692F42E6-41DA-4C43-9F0B-9B33BAD3CB36Q31119657-2AB1AAE8-042E-41E9-81DF-29796D68B8CCQ33194319-BB83435B-9801-4057-888B-F907FED3B032Q33894924-E2083FE2-DC32-4966-B860-D2AAE22D8CC7Q36255766-7FE7349A-9A5D-47B9-984D-0C10FFEACC26Q36349459-7547E080-68E6-49FB-85F2-2CE4D9A75E8FQ36784550-EDC527CF-5091-422E-8A26-C177D4D137D7Q36966415-79FBD549-A666-414D-9E12-38114FEB5A7FQ37012786-005E1DB1-FDA7-484A-9F67-1DF1AE43E85AQ37107029-C534E070-D805-44F1-9A10-DCE39DB61497Q37362990-ADF3A4F4-FE5D-4CA6-A7C3-2F148FC32F38Q38088378-8D41EDE9-5FC6-48FF-A4AB-3242D26CA9B2Q38356102-0A18A6BD-E961-4BC9-915A-9C293A4E8CC8Q38803203-3E63313D-8B8C-4E1D-B58A-D7040A8B9BD1Q40028428-C4A6E92F-D3E7-4DD0-A26F-0C4F8E84DDF6Q40127940-52F03198-B22D-4615-B7D5-FFEC810BA18DQ42642029-B2822939-57BA-4B4F-9F51-2769CD8A9435Q42858959-3B004CE2-2EAC-489B-948F-9DB5A02597C9Q43727375-A367994D-F78E-454F-AED3-062E7F5E75EBQ44902038-A0FECA88-0284-47FE-8CF0-6C463B05B287Q45192037-CB1E3D4C-2087-4FDF-979A-8F6AA4F4B6C1Q47430316-B403715C-991C-4715-95B9-7435ECA33D24Q47784321-98356C8C-E6A4-421E-8DA9-ED9897EC7707Q47912286-34541C00-B4FD-4D56-9D28-D7BE37B6FDDBQ57269513-5CE0902C-B134-4BEF-911C-72EBAC00F1A3
P2860
Statistical challenges in the evaluation of surrogate endpoints in randomized trials.
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Statistical challenges in the evaluation of surrogate endpoints in randomized trials.
@ast
Statistical challenges in the evaluation of surrogate endpoints in randomized trials.
@en
type
label
Statistical challenges in the evaluation of surrogate endpoints in randomized trials.
@ast
Statistical challenges in the evaluation of surrogate endpoints in randomized trials.
@en
prefLabel
Statistical challenges in the evaluation of surrogate endpoints in randomized trials.
@ast
Statistical challenges in the evaluation of surrogate endpoints in randomized trials.
@en
P2093
P50
P1476
Statistical challenges in the evaluation of surrogate endpoints in randomized trials.
@en
P2093
Ariel Alonso
Didier Renard
Helena Geys
P304
P356
10.1016/S0197-2456(02)00236-2
P407
P577
2002-12-01T00:00:00Z